Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

s0122234

4ae10797-fb0d-5d37-9858-93f1a9c18577

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.400
  • IL6_JAK_STAT3_SIGNALING+0.200
  • INTERFERON_GAMMA_RESPONSE+0.200
  • COMPLEMENT+0.100
  • IL2_STAT5_SIGNALING+0.100
  • KRAS_SIGNALING_UP+0.100
  • UV_RESPONSE_DN+0.100
  • APICAL_JUNCTION+0.000
  • HEME_METABOLISM+0.000
  • INFLAMMATORY_RESPONSE+0.000

Top 10 suppressed

  • MYC_TARGETS_V2-0.600
  • CHOLESTEROL_HOMEOSTASIS-0.500
  • E2F_TARGETS-0.500
  • G2M_CHECKPOINT-0.500
  • MTORC1_SIGNALING-0.500
  • MYC_TARGETS_V1-0.500
  • OXIDATIVE_PHOSPHORYLATION-0.500
  • DNA_REPAIR-0.400
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
  • GLYCOLYSIS-0.400

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1ERR2208899
melanoma-umap@29
0.902
2X65f5effa.07f7.4ed3.9e0a.3a0d9d451474
lung-landscapes@6
cohortA10.899
36b907244-c173-4e29-a163-24258a430477
melanoma-umap@29
0.893
4s0112296
melanoma-umap@29
0.888
520030061.LumA
breast-umap@18
A0.888
6TCGA-93-A4JO-01A-21R-A24X-07
lung-landscapes@6
cohortA10.885
7SRR8518276
breast-umap@18
A0.882
8ERR2208971
melanoma-umap@29
0.880
9be8d8236-4ebc-46de-a4fd-a901fec1cdce
melanoma-umap@29
0.875
10SRR12696778
melanoma-umap@29
0.872

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 7 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.400Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.200Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.200Idelalisib— uncovered
COMPLEMENT0.100Inavolisib— uncovered
IL2_STAT5_SIGNALING0.100Idelalisib— uncovered
KRAS_SIGNALING_UP0.100Inavolisib— uncovered
UV_RESPONSE_DN0.100Inavolisib— uncovered